Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jan 18;82(2):278–282. doi: 10.1054/bjoc.1999.0915

ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m−2 and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients

M J Watts 1, S J Ings 1, D Leverett 1, A MacMillan 2, S Devereux 1, A H Goldstone 1, D C Linch 1
PMCID: PMC2363271  PMID: 10646877

Abstract

Cyclophosphamide 1.5 g m−2followed by granulocyte colony-stimulating factor (G-CSF) is an effective peripheral blood stem cell (PBSC) mobilizing regimen, but has limited anti-lymphoma activity. We therefore assessed the mobilizing potential of ESHAP (etoposide, ara-C, methylprednisolone and cisplatin), a potent second-line lymphoma regimen followed by G-CSF. The results were compared in 78 patients with relapsed or resistant lymphomas with the use of cyclophosphamide 1.5 g m−2followed by G-CSF in a matched pairs analysis, matching the ESHAP recipients (for predetermined prognostic factors) from a cohort of 178 lymphoma patients mobilized with cyclophosphamide and G-CSF. The total numbers of mononuclear cells collected at apheresis was similar with both regimens but ESHAP plus G-CSF resulted in a significantly higher percentage of CD34+ cells, absolute number of CD34+ cells and GM-CFC (all with P -values < 0.001). The number of patients requiring only one apheresis harvest to achieve a CD34+ cell yield of > 2.0 × 106kg−1was greatly increased in the ESHAP recipients (56/78 vs 17/78, P< 0.001). The total number of progenitor cells collected was not significantly different with the two mobilization regimens because of this higher number of apheresis in the cyclophosphamide group. The proportion of patients who failed to achieve a minimum CD34+ cell target of 1 × 106kg−1with the pooled harvests was less in the ESHAP arm (four patients vs nine patients) despite an increased number of aphereses in the cyclophosphamide recipients. ESHAP plus G-CSF is well tolerated and is an excellent mobilization regimen in patients with pre treated lymphoma. © 2000 Cancer Research Campaign

Keywords: lymphoma, PBSC, ESHAP, cyclophosphamide, mobilization

Full Text

The Full Text of this article is available as a PDF (64.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bensinger W., Appelbaum F., Rowley S., Storb R., Sanders J., Lilleby K., Gooley T., Demirer T., Schiffman K., Weaver C. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995 Oct;13(10):2547–2555. doi: 10.1200/JCO.1995.13.10.2547. [DOI] [PubMed] [Google Scholar]
  2. Dreger P., Klöss M., Petersen B., Haferlach T., Löffler H., Loeffler M., Schmitz N. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood. 1995 Nov 15;86(10):3970–3978. [PubMed] [Google Scholar]
  3. Goldschmidt H., Hegenbart U., Haas R., Hunstein W. Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant. 1996 May;17(5):691–697. [PubMed] [Google Scholar]
  4. Haas R., Möhle R., Frühauf S., Goldschmidt H., Witt B., Flentje M., Wannenmacher M., Hunstein W. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood. 1994 Jun 15;83(12):3787–3794. [PubMed] [Google Scholar]
  5. Jones H. M., Jones S. A., Watts M. J., Khwaja A., Mills W., Fielding A., Goldstone A. H., Linch D. C. Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma. J Clin Oncol. 1994 Aug;12(8):1693–1702. doi: 10.1200/JCO.1994.12.8.1693. [DOI] [PubMed] [Google Scholar]
  6. McQuaker I. G., Haynes A. P., Stainer C., Anderson S., Russell N. H. Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. Br J Haematol. 1997 Jul;98(1):228–233. doi: 10.1046/j.1365-2141.1997.1812998.x. [DOI] [PubMed] [Google Scholar]
  7. Morton J., Morton A., Bird R., Hutchins C., Durrant S. Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate dose cyclophosphamide and G-CSF. Leuk Res. 1997 Jan;21(1):21–27. doi: 10.1016/s0145-2126(96)00059-8. [DOI] [PubMed] [Google Scholar]
  8. Rowlings P. A., Bayly J. L., Rawling C. M., Juttner C. A., To L. B. A comparison of peripheral blood stem cell mobilisation after chemotherapy with cyclophosphamide as a single agent in doses of 4 g/m2 or 7 g/m2 in patients with advanced cancer. Aust N Z J Med. 1992 Dec;22(6):660–664. doi: 10.1111/j.1445-5994.1992.tb04867.x. [DOI] [PubMed] [Google Scholar]
  9. Schwartzberg L. S., Weaver C. H., Birch R., Manner C., Tauer K., Beeker T., Morgan-Ihrig C., MacAneny B., Leff R., Smith R. A randomized trial of two doses of cyclophosphamide with etoposide and G-CSF for mobilization of peripheral blood stem cells in 318 patients with stage II-III breast cancer. J Hematother. 1998 Apr;7(2):141–150. doi: 10.1089/scd.1.1998.7.141. [DOI] [PubMed] [Google Scholar]
  10. Velasquez W. S., McLaughlin P., Tucker S., Hagemeister F. B., Swan F., Rodriguez M. A., Romaguera J., Rubenstein E., Cabanillas F. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994 Jun;12(6):1169–1176. doi: 10.1200/JCO.1994.12.6.1169. [DOI] [PubMed] [Google Scholar]
  11. Watts M. J., Linch D. C. Peripheral blood stem cell transplantation. Vox Sang. 1997;73(3):135–142. doi: 10.1046/j.1423-0410.1997.7330135.x. [DOI] [PubMed] [Google Scholar]
  12. Watts M. J., Sullivan A. M., Ings S. J., Leverett D., Peniket A. J., Perry A. R., Williams C. D., Devereux S., Goldstone A. H., Linch D. C. Evaluation of clinical scale CD34+ cell purification: experience of 71 immunoaffinity column procedures. Bone Marrow Transplant. 1997 Jul;20(2):157–162. doi: 10.1038/sj.bmt.1700879. [DOI] [PubMed] [Google Scholar]
  13. Watts M. J., Sullivan A. M., Jamieson E., Pearce R., Fielding A., Devereux S., Goldstone A. H., Linch D. C. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol. 1997 Feb;15(2):535–546. doi: 10.1200/JCO.1997.15.2.535. [DOI] [PubMed] [Google Scholar]
  14. Watts M. J., Sullivan A. M., Leverett D., Peniket A. J., Perry A. R., Williams C. D., Devereux S., Goldstone A. H., Linch D. C. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization. J Clin Oncol. 1998 Apr;16(4):1554–1560. doi: 10.1200/JCO.1998.16.4.1554. [DOI] [PubMed] [Google Scholar]
  15. Weaver C. H., Zhen B., Buckner C. D. Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34+ peripheral blood stem cells. Bone Marrow Transplant. 1998 Jun;21(11):1169–1170. doi: 10.1038/sj.bmt.1701254. [DOI] [PubMed] [Google Scholar]
  16. Zinzani P. L., Barbieri E., Visani G., Gherlinzoni F., Perini F., Neri S., Bendandi M., Ammendolia I., Salvucci M., Babini L. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease. Haematologica. 1994 Nov-Dec;79(6):508–512. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES